Olfr48, a crucial olfactory receptor, orchestrates the intricate process of odor detection within olfactory sensory neurons, contributing significantly to the nuanced sense of smell. As a G protein-coupled receptor (GPCR), Olfr48 is expressed in these neurons, where it serves as a molecular sensor for specific odorant molecules. Upon activation by odorants, Olfr48 initiates a series of signaling events, leading to the transduction of olfactory signals and eventual perception of distinct smells in the brain. This receptor plays a pivotal role in discerning a wide array of odorants, enabling organisms to navigate and interact with their environments based on olfactory cues. The inhibition of Olfr48 involves a multifaceted interplay with intricate cellular pathways, emphasizing the dynamic nature of its regulation. Direct inhibitors, such as phosphodiesterase inhibitors, disrupt the cyclic AMP (cAMP) signaling cascade, thereby modulating Olfr48 expression indirectly by influencing downstream pathways. Epigenetic modulation through histone deacetylase (HDAC) inhibitors alters the chromatin landscape, impacting the accessibility of Olfr48's promoter region and, consequently, its expression. Furthermore, modulation of key signaling pathways, exemplified by MEK inhibitors affecting the MAPK pathway, indirectly influences Olfr48 expression by altering the phosphorylation state of proteins within the signaling cascade, thereby shaping gene expression.
Calcium channel blockers and PI3K inhibitors also contribute to indirect Olfr48 inhibition by disrupting intracellular calcium levels and affecting the Akt/mTOR pathway, respectively. GPCR antagonists interfere with receptors upstream of Olfr48, modulating signal transduction and inhibiting Olfr48 expression indirectly. Additionally, inhibitors targeting nuclear factor-kappa B (NF-κB), Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, Wnt pathway, AMP-activated protein kinase (AMPK), toll-like receptors (TLRs), and Notch pathway showcase diverse mechanisms of Olfr48 modulation, each influencing gene expression through distinct cellular processes. This intricate interplay of chemical modulators highlights the regulatory complexity involved in controlling Olfr48 function, providing valuable insights into the molecular mechanisms governing olfactory perception.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Phosphodiesterase 4 inhibitor disrupting cAMP signaling. Increased cAMP levels alter Olfr48 expression indirectly by modulating downstream pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor impacting chromatin remodeling. Alters the epigenetic landscape, affecting Olfr48 expression by influencing the accessibility of its promoter. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor targeting the MAPK pathway. Indirectly inhibits Olfr48 by altering the phosphorylation state of proteins in the signaling cascade, impacting gene expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker disrupting intracellular calcium levels. Indirectly influences Olfr48 by interfering with calcium-dependent signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting Akt/mTOR pathway. Alters Olfr48 expression indirectly through the modulation of downstream effectors in the PI3K signaling cascade. | ||||||
Olanzapine | 132539-06-1 | sc-212469 | 100 mg | $130.00 | 6 | |
GPCR antagonist targeting receptors upstream of Olfr48. Modulates signal transduction, indirectly inhibiting Olfr48 expression by interfering with receptor activation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB inhibitor attenuating inflammatory signaling. Indirectly inhibits Olfr48 expression by suppressing NF-κB-mediated transcriptional regulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK/STAT pathway inhibitor. Modulates Olfr48 expression indirectly by disrupting cytokine signaling through the inhibition of JAK and STAT signaling components. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
Wnt pathway antagonist. Indirectly inhibits Olfr48 by interfering with the Wnt signaling cascade, impacting downstream events involved in gene expression. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
AMPK activator influencing energy sensing. Indirectly inhibits Olfr48 by regulating cellular energy status, affecting pathways linked to gene expression. | ||||||